Significant variability in the pharmacokinetics of drugs such as cyclosporine, tacrolimus, sirolimus and mycophenolic acid, is seen in liver transplant patients. These agents are primarily metabolized by CYP3A4 or UGT1A1, and are also substrates for drug transporters such as P-glycoprotein, multidrug resistance protein 2 (MRP2) and bile salt export pump (BSEP). Factors modulating the expression and activity of these enzymes and transporters will lead to changes in the clearance of immunosuppressive agents. Inflammation associated with infection or organ rejection after transplantation can modulate the expression and activity of CYP3A4, UGT1A1 and various drug transporters. HIV-protease inhibitors (HIV-PIs) used for the treatment of HIV infe...
Pharmacokinetic (PK) interactions between protease inhibitors (PI(s)) and immunosuppressive agents (...
Using sandwich-cultured hepatocytes from rat, dog, pig, and human, we investigated the species-speci...
Lopinavir and ritonavir are protease inhibitors available as a coformulation for the management of H...
Significant variability in the pharmacokinetics of drugs such as cyclosporine, tacrolimus, sirolimus...
Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failur...
Correct dosing in pharmacotherapeutics is based on the idea that too much of a drug will cause toxic...
The aim of this work was to explore the contribution of the organic anion transporting polypeptide-1...
Thesis (Ph.D.)--University of Washington, 2012The HIV Protease inhibitor (PI)-based DDIs are complex...
Hepatic regeneration is essential for the success of living donor liver transplantation (LDLT) in wh...
Individual differences in pharmacokinetics may cause extensive variability in drug efficacy, toxicit...
Solid organ transplantation in human immunodeficiency virus 1 (HIV)-infected individuals requiring t...
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immunosuppressive agent t...
Together with drug metabolising enzymes, transmembrane transporters are important determinants of dr...
Hepatotoxicity has been reported as side-effect in some patients on HIV protease inhibitors (PI). Si...
Three decades of hepatocyte transplantation have confirmed such a cell-based approach as an adjunct ...
Pharmacokinetic (PK) interactions between protease inhibitors (PI(s)) and immunosuppressive agents (...
Using sandwich-cultured hepatocytes from rat, dog, pig, and human, we investigated the species-speci...
Lopinavir and ritonavir are protease inhibitors available as a coformulation for the management of H...
Significant variability in the pharmacokinetics of drugs such as cyclosporine, tacrolimus, sirolimus...
Organ transplantation is an accepted therapy for diseases that result in chronic irreversible failur...
Correct dosing in pharmacotherapeutics is based on the idea that too much of a drug will cause toxic...
The aim of this work was to explore the contribution of the organic anion transporting polypeptide-1...
Thesis (Ph.D.)--University of Washington, 2012The HIV Protease inhibitor (PI)-based DDIs are complex...
Hepatic regeneration is essential for the success of living donor liver transplantation (LDLT) in wh...
Individual differences in pharmacokinetics may cause extensive variability in drug efficacy, toxicit...
Solid organ transplantation in human immunodeficiency virus 1 (HIV)-infected individuals requiring t...
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immunosuppressive agent t...
Together with drug metabolising enzymes, transmembrane transporters are important determinants of dr...
Hepatotoxicity has been reported as side-effect in some patients on HIV protease inhibitors (PI). Si...
Three decades of hepatocyte transplantation have confirmed such a cell-based approach as an adjunct ...
Pharmacokinetic (PK) interactions between protease inhibitors (PI(s)) and immunosuppressive agents (...
Using sandwich-cultured hepatocytes from rat, dog, pig, and human, we investigated the species-speci...
Lopinavir and ritonavir are protease inhibitors available as a coformulation for the management of H...